Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.

  • Paul Coppo
  • Published 2017 in
    Transfusion and apheresis science : official…


Daily therapeutic plasma exchange (TPE) transformed the historically fatal prognosis of acquired, anti-ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura (TTP), leading to the current overall survival rates of >80%. However, relapses occur in up to 40% of patients and refractory disease with fatal outcomes still occurs. In this context, the… (More)
DOI: 10.1016/j.transci.2016.12.019